Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies

Conclusions We suggest that FGFR2 inhibition has potent effects on ovarian cancer growth in preclinical studies.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research